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GLOSSARY

Within this document several terms are used that require definition. The definition of those
terms are as follows:
CAPA- Corrective Action and Preventive Action. Structured, formalized way to investigate nonconformance used to determine the root cause and find the appropriate correction,
corrective actions and preventive actions and measure their effectiveness.
Corrective action- Defined as the action taken to eliminate the causes of an existing
nonconformity, defect, or other undesirable situation in order to prevent recurrence.
FDA Form 483 notifies the company’s management of objectionable conditions. At the
conclusion of an inspection, the FDA Form 483 is presented and discussed with the
company’s senior management. Companies are encouraged to respond to the FDA Form
483 in writing with their corrective action plan and then implement that corrective action
plan expeditiously.
Medical device: an instrument, apparatus, implement, machine, contrivance, implant, in vitro
reagent, or other similar or related article, including a component part, or accessory
which is recognized in the official National Formulary, or the United States
Pharmacopoeia, or any supplement to them, intended for use in the diagnosis of disease
or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man
or other animals, or intended to affect the structure or any function of the body of man or
other animals, and which does not achieve any of its primary intended purposes through
chemical action within or on the body of man or other animals and which is not
dependent upon being metabolized for the achievement of any of its primary intended
purposes.

x
Warning letter: A Warning Letter is the FDA's advisory notice that you have significantly
violated FDA regulations. It will identify the violation(s) and make it clear that you must
correct the problems and inform the FDA of your specific plans for correction of the
problem, including actions to prevent it or a similar problem from re-occurring.
Preventive action: Defined as the action taken to eliminate the causes of
a potential nonconformity, defect, or other undesirable situation in order to prevent
occurrence.
Regulatory Authorities: Governmental Agencies that responsible in effective drug/medical
device regulation required to ensure the safety, efficacy and quality of drugs/medical
devices, as well as the accuracy and appropriateness of the drug/ medical device
information available to the public.
Six Sigma: Is a technique that provides organizations tools to enhance the capability of their
business processes. This increase in performance and decrease in process variation lead
to defect reduction and improvement in profits, employee morale, and quality of
products or services. Six Sigma quality is a term generally used to indicate a process is
well controlled (within process limits ±3s from the center line in a control chart, and
requirements/tolerance limits ±6s from the center line).

xi

LIST OF ABBREVIATIONS

CAPA: Corrective action and preventive action
CFR: Code of Federal Regulation
DMAIC: Define, Measure, Analyze, Improve, and Control
FDA: Food and Drug Administration
FOI: free for information act
FOI: Free of information
IRB: Institutional Review board
LOD: Limit of detection
SS: six Sigma
StN: Signal to noise
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ABSTRACT

Author: Nour, Reham, O. MS
Institution: Purdue University
Degree Received: May 2018
Title: GOOD CAPA PRACTICE - A SIX SIGMA APPROACH TO REDUCE COST OF NONCOMPLIANCE
Committee Chair: Geanie Umberger
Within pharmaceutical and medical devices-based industries, there are no generalized or
standardized procedures for design, implement, and control a compliance CAPA structure.
Simultaneously, FDA observation reports and warning letters revealed that CAPA is still not
fully understood by many of pharmaceutical/medical devices manufacturing community
members.
This study expands knowledge in the field of quality system regulation by offering methods
and tools that work efficiently within the CAPA structure. while, at the same time, sustaining
productivity through critical evaluation of FDA warning letters which considered a great tool for

professionals and researchers. This provide a great insight on how to build in and implement the
FDA regulations and requirements into companies’ quality system. On the other hand, using Six
Sigma DMAIC principle in improving CAPA system compliance performance helps define the
bottlenecks and sources of variations within the CAPA process.
Two main focus for this research, first to identify the criteria for Good CAPA Practice and
second to use Six Sigma DMAIC (define, measure, analyze, improve, control) approach to
enhance CAPA compliance performance and therefore decrease the cost of non-compliance. As
such, Six Sigma DMAIC principle implemented to improve the CAPA system for a medical
device company as a case study. Finally, a stepwise-based model was developed to ensure best
compliance with FDA requirements and regulations within the whole course of CAPA system at

xiii
all quality and business levels. This CAPA model significantly helps companies in their
continuous improvement journey to reach out their ultimate goals at all business aspects.
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INTRODUCTION

Within pharmaceutical sector, implementing an effective corrective action and preventive
action (CAPA) system is something critical, not only because it is a regulatory requirement, but,
because it is a helpful tool for continuous improvement in order to achieve superior quality,
excellence operation, and improve the organization performance. It is mandatory by the
regulatory bodies, the U.S. Food and Drug Administration (FDA), that drug and medical
devices-based industries, establish and implement a robust and effective CAPA structure. A
robust and effective CAPA structure allows companies to collect possible quality data, evaluate
all relevant information to define quality issues, investigate the possible root causes, and
eventually, implement an effective corrective/preventive action to avoid relapse. Therefore, a
mature CAPA system is needed for:
-

Regulatory requirements- A prerequisite for ISO certified and FDA regulated companies.

-

Customer Satisfaction- Capability to deal with any customer related issue and correct
any quality problem is crucial for better customer relationship and sustained satisfaction.

-

Better business performance- Problems and quality issues would financially impact
companies.

Simultaneously, Six Sigma is a tactical methodology used in all industrial sectors for about 25
years to improve process performance. It was established by Motorola in the 1980’s and started to
be implemented by others after General Electric. Six Sigma is a flexible data-driven approach used
by the most successful leadership in the world to save lots money, to improve capabilities and
performance, to achieve better customer relationships and therefore, achieve near perfection
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performance at all business level. This approach relies on facts and statistical analytical thinking
to detect and eliminate the non-desirable variations and defects in the business processes.
Organizations need to implement Six Sigma DMIC principles as a business strategy and
methodology that improves business performance and operational efficiency, improve product
quality, reduce production costs, and improve customer satisfaction, especially considering the
growth of global markets.
Within organization, Six Sigma could be used as a catalyst for compliance, it consists of several
components that ensure the effective running and implementation of regulatory compliance
program. Six Sigma allows a more consistent compliance program consistently. Although,
consistency and meeting expectations may seem boring, they are good things in the compliance
world.
Using Six Sigma in the pharmaceutical industry required that extra care is taken when
identifying the customer as the customer definition is varied in this industry compared to many
other industries. For pharmaceutical industries, although the patients are the end customers, there
are third-party customers. The real customers are the doctors prescribing drugs, the pharmacist
willing to stock certain medicine and the governments who oversee socialized healthcare. These
governments have enormous buying power and wield this power to negotiate pricing of
pharmaceutical products.
Therefore, pharmaceutical organization should consider these regulatory agencies as one of
their customers who help generate additional revenue and profits. Six Sigma can be used to
improve the CAPA process by considering the FDA as the customer for CAPA and define their
critical requirements then using the model Define, Measure, Analyze, Improve, and Control
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(DMAIC) to improve the CAPA process performance and further maintain this improved
performance.
Subsequently, the unification of the Six Sigma with the good CAPA practice enhance the
efficiency and effectiveness and assist in achieving outstanding performance. This could be
achieved by adopting the concept and benefits of Six Sigma in order to reach an effective CAPA
system (Good CAPA practice) to help run a more efficient and productive business.

1.1

Scope

FDA enforced regulations for CAPA structure found under FDA 21 CFR 820.100. The FDA
forces drug/medical devices-based industries to develop and implement well written standard
operating procedure(s) for all activities applied within the company to correct/prevent nondesirable issues. Not only FDA, there are many other international standards and regulatory
authorities imbedded CAPA requirements and regulations. For example, ISO 13485:2016 enforces
medical device companies seeking to be ISO 13485:2016 certified to develop and implement
corrective/preventive actions activities under section 8.5.2 and section 8.5.3.
Bearing in mind the unique functional purposes for CAPA program in collecting all
possible quality data, evaluating all relevant information to define quality issues, investigating
the possible root causes, and eventually, implementing an effective action to avoid relapse. This
research is limited to the CAPA system as an essential part of any properly functioning quality
system and an important requirement within pharmaceutical/medical device regulations.
However, based on the observations appearing in FDA observation reports and warning letters,
CAPA is still not fully understood by many pharmaceutical/medical devices manufacturing
community members. Additionally, the scope of this research is limited to identifying the criteria
for Good CAPA Practice and implementing the Six Sigma DMAIC (define, measure, analyze,
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improve, control) approach to enhance CAPA compliance performance and therefore decrease
the cost of non-compliance. As such, CAPA system improvements using Six Sigma DMAIC
methodology will be performed on a medical device company as a case study.

1.2

Significance

Each pharmaceutical/medical device manufacturer knows that an effective CAPA structure is
required for conducting business while complying the FDA guidelines.
This research expands knowledge in the field of quality system regulation by offering
methods and tools that work efficiently within the CAPA structure, while, at the same time,
sustaining productivity. This can be achieved by providing a best-practices approach that
conducts an effective investigation to recognize root causes and apply a viable corrective action
in a timely manner. Quick and detailed investigations that steadily crop the root causes are
significant to a successful CAPA system. The provocation is to implement a repeatable,
consistent process that can look over both simple and complex CAPAs. This research serves as a
guide for the pharmaceutical/medical device manufacturer to comply with the FDA, conduct
good business practice, and avoid cost of being non-compliance. Additionally, by providing a
novel interactive application of Six Sigma DMAIC methodology in improving CAPA process
will allow pharmaceutical/medical device manufacturer to gain greater understanding on how to
conduct effective CAPA program, yet extremely important, to bring the best results needed for
forward tractions.

1.3

Problem Statement

Many of the drug and medical devices- based industries are experiencing a problem with
their corrective and preventive action (CAPA) systems. According to the FDA, more than half of
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the issued warning letters cite CAPA deficiencies. Inadequate corrective and preventive actions
create many challenges, such as reoccurrence of deviations, duplication and rework, quality
issues, and increased costs. The magnitude of an immature CAPA system is reflected by the risk
associated. First, the risk of non-compliance with the regulatory requirement, both the FDA and
ISO, require an active CAPA program as an essential element of a quality system. Secondly,
failure to address customer needs and the ability to correct existing problems or implement
controls to prevent potential problems are essential for continued customer satisfaction. Finally,
an immature CAPA system adversely affects business practice; quality problems can have a
significant financial impact on a company. Thus, an ineffective CAPA system negatively impacts
the product quality and, therefore, patient safety.

1.4

Research Questions

The main research questions of this study are:
1. What can be learned from the existing FDA warning letters that cited corrective and
preventive action (CAPA) violations to understand the FDA critical requirement for CAPA
system and therefore, define the norms and criteria for Good CAPA Practices?
2. How can the effectiveness of corrective and preventive action process be improved using SixSigma DMAIC principles?

1.5

Assumptions

The following assumptions are identified as part of this research proposal:
•

CAPA system will be considered a process.

•

Six Sigma can be used to improve process effectiveness.
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•

Data provided by the case study company is accurate and their CAPA software is
validated.

•

FDA Database is up to date.

1.6

Limitations

The following limitations are identified as part of this research proposal:
•

This research will review only the aspects of CAPA regulation.

•

This research focused only on Drug related and medical device related companies.

•

This study will use Six Sigma methodology as a process improvement tool to improve
CAPA process effectiveness. Other process improvement tools will not be tested by this
study.

•

This study analyzes the FDA warning letter which cited only CAPA violations.

•

The last stage of the DMAIC approach (control stages) will be delivered to the case study
company as suggestions and recommendations.

1.7

Delimitations

The following limitations are identified as part of this research proposal:
•

This study will not focus on food or cosmetics or tobacco products regulated by FDA.

•

There are various regulations and guidelines that required CAPA implementation;
however, this study will only focus on FDA requirements.

•

When bearing in mind process improvement both efficiency and effectiveness should
be considered. However, this study will focus only on improving the effectiveness of
the CAPA process.
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1.8

Chapter Summary

This chapter has described the main motivation of this study as well as it presented the
scope, significance and research questions with a detailed list of assumptions, limitations and
delimitations. The next chapter presents a brief summary of relevant literature covering
corrective action and preventive action requirements and notes the apparent gap within literature.
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LITERATURE REVIEW

The Food, Drug, and Cosmetic Act is a federal law, through which FDA legally enforces
pharmaceutical/medical devices-based industries to be totally fulfill all the related regulations
and requirements of the agency. Thus, the FDA’s warning letters to a company regarding quality
systems could conceivably include the following: notice that products become adulterated
because the quality system is not in conformance with FDA requirements. Thus, all products
manufactured by this company are nonconforming products because they do not meet the
specification of the Act which prohibits adulterated products.

2.1

Corrective action and preventive action

One of the specific requirements of the FDA for pharmaceuticals and medical device
companies is that “Each manufacturer shall establish and maintain procedures for implementing
corrective and preventive action (CAPA). Procedures must ensure all requirements of CAPA
subsystem are met”. According to FDA, “Establish means define, document, and implement a
process for CAPA” (Sec. 820.100 Corrective and preventive action).
To initiate corrective/preventive action within the company, there must always be a welldefined and documented reason. This reason is termed “nonconformance”. Nonconformance is a
key concept for quality systems that is frequently overlooked as companies focus on corrective
and preventive action system.
2.1.1 CAPA in the Guidelines
The main sources of CAPA regulations are the current good manufacturing practice
(cGMP) for finished drugs (Title 21 CFR §210 & 211) and the medical devices quality system
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regulation (QSR) contained in Title 21 CFR §820. It is mandatory for any pharmaceuticals and
medical device companies regulated by FDA to have a process in place to identify and correct
quality issues and prevent this issues from recurring in the future.
The first CAPA legal enforced requirements in the United States are recognized in the
21 Code of Federal Regulations (CFR) issued in 1971. Parts 210; Current manufacturing
practice in manufacturing, processing, packing, or holding of drugs and part 211; Current
manufacturing practice for finished pharmaceuticals. In 1978 and 1995, the two regulations are
totally revised.
Current good manufacturing practices (cGMP), the quality systems for FDA-regulated
products (food, drugs, biologics, and medical devices) rules and regulations are first became
legally enforced by Section 520(f) of the Federal Food, Drug, and Cosmetic Act. In December
18, 1978 The Federal Food, Drug, and Cosmetic Act became officially active within part 820
(U.S. Department of Health and Human Services, 201la).
In 1980s, the prevention concept was introduced and implemented as an essential part in
the quality management system (QMS) standards and regulations. Before 1980s, the cGMP
helped quality affairs professionals in using inspection technique to detect and evaluate problems
before a final customer did.
A federal court judge from New Jersey took decision to recall millions of Barr
Laboratories drug products in 1993 (United States v Barr Laboratories, Inc. 1993). When the
FDA claimed that that company’s products are misbrand and adulterated. In 1992, The FDA took
a legal action and sued the company in order to prevent the company from producing and
marketing drugs of poor quality. After reviewing and assessment of four years of FDA
investigators inspection reports, which had widespread manufacturing deficiencies, the judge
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decided that the company’s quality system was poor to fulfill the quality requirements per the 21
C.F.R. § 210 and C.F.R. § 211 and eventually, decided that the company’s products are
adulterated (U.S. v. Barr Laboratories, Inc., 1993) (P.11.)
This was a pioneering decision. It supported the legal power for the concept “you can’t test a
product into compliance” (Pérez, 2011). Moreover, it also established some requirements for
failure investigation additional to those already included in CGMP.
In the 1990s, FDA adapted the CAPA acronym while generating the medical device
quality system guideline. In 1997, The Medical Devices: Current Good Manufacturing Practice
(cGMP) Final Rule: Quality System Regulations (QSR) turned out to be effective. Subpart J (21
C.F.R. § 820.100), states that, “Each manufacturer shall establish and maintain procedures for
implementing corrective and preventive action...” additionally, “All activities required under this
section, and their results, shall be documented” (Sec. 820.100 Corrective and preventive action).
In 1999, FDA issued a 10 steps guideline that outlines detailed information regarding CAPA
subsystem named the Quality System Inspection Technique (QSIT).
The International Organization for Standardization (ISO) plays an important role in
outlying CAPA regulation. In 2000, CAPA requirements are included in QMS standard (ISO
9001:2000) which updated on 2008 with no change for the CAPA requirements. In 2003, the
ISO 13485:2003 was issued to provide the quality standard for medical devices companies.

CAPA in the guidelines
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• FDA Pharmaceutical
CGMP (Title 21 C.F.R. §
210 & 211)
• U.S. vs. Barr
Laboratories, Inc.
Decision
• FDA Medical Devices
QSR (Title 21 C.F.R. §
820)
• FDA Quality System
Inspection Technique
(QSIT)
• FDA Investigation Out
of Specification (OOS)
Guidance

•European
Pharmaceutical GMP
(EudraLex volume 4)
•The Pharmaceutical
Inspection Convention
and Pharmaceutical
Inspection Co-operation
Scheme (PIC/S)

•'ICH Q10 Pharmaceutical
Quality System
•ISO 13485:2003 and the
Non-U.S. Medical
Devices Regulations
•Harmonization Processes
'ICH and GHTF

Figure 2.1 CAPA regulation development

Figure 2.1 summarize the guidelines that have major CAPA requirements in USA,
Europe, and international standards. The criticality of CAPA structure arises from its essential
key role in the overall quality system. It is directly linked to other controlled management
systems within organizations. Therefore, any problems within the CAPA structure will have
significant impact on these systems. Additionally, FDA considers the CAPA program a major
part of a company's quality system and legally forces pharmaceutical/ medical device companies
operates to establish a well-structured CAPA program. Therefore, a healthy CAPA structure
within the company is the key to maintain a healthy total quality management system at all
levels.
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2.1.2

CAPA in the literature

Over the years, many literatures tried to help pharmaceutical and medical devices
company to design, develop, and implement an effective CAPA system and to ensure that
company is following FDA CAPA regulations and requirements. The next paragraphs will
outline most of the published literatures regarding CAPA system starting from 1999 and going
forward.
Singer (1999) emphasize the main points that need to be taken into consideration before
FDA conduct an inspection under the QSIT corrective and preventive actions subsystem. The
CAPA concept is a generally accepted concept in most quality systems, whether ISO, or any
other standard or guideline and is not limited to the Quality system regulation or Quality system
inspection technique. An effective CAPA system needs to be a “closed loop” by providing input
to its quality system, define the root cause of the quality problem and take an appropriate
corrective action in to ensure that the nonconformity problem will not recurring with any similar
situations.
Schnoll (2001) explain under CAPA umbrella the activities and procedures that any
medical devices company regulated under FDA needs to implement within its quality system to
remove the cause of potential nonconforming issues.
Paradies and Skompski (2002) pointed out the reasons behind ineffective corrective
action. Referring that to three main failure factors; first, fix quality problems without critical
analysis to determine the actual root causes of the problem; second, lacking management
commitment and involvement to solve problems; and third, when people working on creating
corrective actions can't think "Outside the Box".
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On the other hand, Snyder (2002) provided significant and realistic vision based on the
right prospective to develop the right strategy and plan using effective tools in order to create an
effective CAPA system as a success factor. Snyder (2002) highlighted the importance of
developing a strategic approach when it comes to planning for CAPA. Successful CAPA can be
ensured through the right strategic planning approach that helps built-in the success factors into
the plan and help in considering the broader context of enforcement action and therefore, reduce
cost of nonconformance.
Peterson (2005) reports another success factor, which is well trained team on CAPA
investigation. This team could effectively collaborate and communicate with others using
“critical thinking” tools to define the main problems root causes. Peterson (2005) pointed out
that the more the awareness of companies’ personnel with the technique and tools for root cause
analysis, the more well performance of investigations activities that therefore, lead to more
effectual problem solving.
Paradies (2007) introduced “common-sense approaches for improvement” by applying a
well-established approach for process efficiency improvement such as Lean thinking introduced
by Toyota (the Toyota Production System) to eliminate waste and enhance the root cause
analysis effectiveness and problems investigation. Using lean thinking creates realistic, but
unusual “out of box” ideas to enhance the CAPA system.
The significance of implementing effective preventive action to ensure effective and
consistence achievement of all business and quality objectives was emphasized by Hoffman
(Hoffman, 2007). According to Hoffman, this can be achieved through characterization and
monitoring of products, services, and processes. Pointing out the significance of implementing a
strong preventive action process within the pharmaceutical and medical devices companies as
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required by quality management system QMS standards. Hoffman (2007) enlightens the main
different points “between CAPA and purely preventive action” as pure preventive action is a
voluntary action, planed and implemented before any problem or nonconformity occurs. On the
other hand, in case of CAPA, a nonconformity or problem has been occurred and detected and
therefore, a mandatory action needs to be taken.
Factually, pharmaceutical and medical devices companies have not paid enough attention
to CAPA programs and CAPA management (Biswas, 2008). Biswas suggested that, strengthen
the compliance focus can be achieved through implementing CAPA as an improvement tool to
the organization main activity. This improvement function should be used by teams throughout
the organization as an efficiency enhancement function and not just as a requirement for
compliance. Good CAPA management strategy with adequate support from a strong IT system
improves both compliance with quality regulation and productivity, creating the perception of a
“good quality system practices” organization and assist in developing a product that drives
satisfaction to both customer and regulatory authorities.
Van Wert (2008) asserted that for all CAPA investigations the challenge is to understand
that there will be an endless number of solutions for statistically derived problems at or below
the limit of detection LOD. Additionally, it was declared that the key for effective CAPA system
is to understand the relationship of “signal-to-noise” (StN) process approach. According to Van
Wert this approach is valuable in addressing CAPA investigations through differentiation
between real process excursions and process variations. The author also suggested five
considerations that help define the problem and put it into the right investigation, causing CAPA
to be more effective and practical in identifying critical to quality attributes under the following
key actions for successful CAPA implementation; “control of impacted product, evaluating
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design controls, action determination, changing system controls if warranted, and monitoring
effectiveness (p. 44).”
Bodea (2008) emphasized through two articles published on 2008, what companies need
to construct a new CAPA system from scratch and the most important consideration that
companies should understand when developing CAPA system by introducing the different
aspects of CAPA system and what should be accomplished by an effective CAPA system.
Effective CAPA system should have effective CAPA policy, well-written procedures, strong IT
support, good planning, well-trained team, appropriate actions taken, and effective measure of
the process performance.
The important of building a control CAPA system was demonstrated by Hodges in 2010
through four essentials main components of any CAPA program that will prove control over the
processes: “documentation, investigation, CAPA, and measurement” (Hodges, 2010, p. 27).
Hodges (2010) implied that, between these four elements, measurement is the most important
element, measuring and trending quality problem through different categories based on
personnel, processes, equipment, or impact process area can help better provision of resources
for continuous quality improvement. Maintaining an effective CAPA system will allow a reliable
and unbiased insight at how the companies manage their processes and demonstrate control, risk
elimination, and cost reduction, which are efficient key indicators of the company’s focus and
commitment to quality.
Hardoroudi et al. (2011) introduced another four divisions for a robust CAPA system which
offers compatibility with the organization’s quality system. The four divisions of this robust
system are; “gathering information and data, investigation, clarification and making decision”.
The authors tried to develop an effective CAPA system based on these four divisions to allow
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managers to rank and track problems to get better efficiency, mitigate risk and address some
control condition.
Kozloski (2014) defined a list of 10 Critical to Quality (CTQs) attributes through
comparing five sets of CAPA regulations—Current Good Manufacturing Practices (cGMP) for
Finished Pharmaceuticals (21 C.F.R. § 211), the Quality System Regulation (21 C.F.R. §
820.100, Subpart J), the QMS Standard (ISO 9001:2008), the QMS Standard for Medical
Devices (ISO 13485:2003), and FDA Quality System Inspection Technique (QSIT), a detailed
FDA Guidance Document for CAPA. Additionally, a list of CAPA process Key Performance
Indicators (KPIs) was created based on vision analysis of 10 CAPA professionals. Kozloski
declared that both lists of CTQs and KPIs help FDA-regulated organization to design, develop,
and implement an effective and compliance CAPA system.
Continuing with the success factor for a robust and effective CAPA system, Mehta
(2014) enlightened the importance of effective root cause analysis as a success factor for
pursuing a robust CAPA system. Inaccurate root cause analysis will increase the probability of
implementing the wrong solution and therefore, impact the safety, quality, and efficacy of the
product. Mehta (2014) as a principal consultant provided his Perspective on how to perform
effective root cause analysis and the reasons that derived FDA to issue warning letter from
CAPA compliance prospective.
Raj (2016) provided a comprehended overview of CAPA system requirements based on
the 21 CFR 820 regulatory requirements for CAPA system. Raj discussed these requirements to
be; Preamble on procedures, establishing data sources, data analysis (non-statistical and
statistical techniques), investigation to determine root cause, identify corrective and preventive
actions, the preamble on risk and degree of corrective and preventive action, verify/validate
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corrective and preventive actions, communicating CAPA information, the preamble on CAPA
activities for management review, and documenting corrective action and preventive action
activities. Table 2.2 summarizes all the CAPA aspects that most CAPA professionals try to
address.

Table 2.2. CAPA in the literatures

Despite all these guidelines and regulation, data presented from evaluation of FDA
warning letters shows Corrective and Preventive Action (CAPA) still one of the top observed
citations in FDA warning letters which imply that, CAPA still not fully understood by
companies.
The common thing between all these Guidelines and publication is that, all of them tried
to discuss the regulations in more details to help the pharmaceuticals and medical devices
manufacturers to better understand the requirements of CAPA system regulations and to how to
implement each requirement, through a focus on both the failure and success factors for effective
CAPA system or through suggestion of the essential elements for CAPA system from the author
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point of view. However, they fail to provide the companies with robust and effective ways to
evaluate and measure their performance in relative to the FDA regulation requirement and
therefore, find out the drawbacks and the weakness into their CAPA system. All these
publications did not discuss the rationale for discrepancies in CAPA reports or how to reduce
process variations and how to develop consistence process. the literature does not discuss how or
why CAPA system fail to define criteria that an FDA inspector looks for during CAPA
investigations and fail to provide suggestions to avoid these drawbacks.
This study defines the FDA critical requirement for CAPA system that will help the
pharmaceutical and medical devices companies to evaluate their current CAPA system
performance. It also defines the criteria that an FDA inspector looks for during CAPA
investigations to provide the pharmaceutical and medical device companies with an organized
approach to help them develop a robust and effective CAPA system for better compliance with
FDA regulation, better customer satisfaction, and good business practices. This will be
conducted through evaluation and analysis of all warning letters issued to both pharmaceutical
and medical device companies by the FDA during the last five years.

2.2

Six Sigma DMAIC principles

Although, there are some drug and medical devices-based companies that have
implemented Six Sigma and are successfully using it to accomplish their corporate strategy such
as Baxter, Eli Lilly, Johnson & Johnson and Novartis (Stückrath 2006), only a few of them are
listed among the member companies of the International Society for Six Sigma Professionals
(ISSSP) (Liu 2005). Although this industrial sector is highly regulated in order to make sure that
all the regulatory requirements are followed and implemented by the companies to produce and
deliver a high quality product and therefore, protect the patients safety, there are many critical
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processes are not meeting the needs of today’s market and the unique customers of this sector
(Cortada et al, 2004) Find and follow a strategic methodology that helps companies maintain
their best compliance status and achieve continuous business improvement is the key. Tarantino
(2008) pointed out that having a six Sigma program in place could help the organization in many
ways. One of them is through reducing variation which is what the compliance program aims to
produce consistently. Therefore, for the CAPA process, this thesis assumed that Six Sigma is a
great tactical methodology that can be adapted by pharmaceutical and medical devices-based
companies to bring the best compliance, which is the primary FDA required deliverables to the
hands of the CAPA process customer (FDA).this is because Six Sigma itself is not a statistical
tool, it is a tactical methodology used to produce quantifiable and significant change within the
company using statistical data to operate the compliance systems and processes to the maximum
possible compliance performance, or near perfect compliance levels in order to finally improve
customers’ satisfaction (FDA) and reduce compliance costs (Roan & Jernelid, 2009). Therefore,
the target goal for CAPA process improvement is to bring the process to the maximum
compliance as well as reduce the cost of non-compliance. This is complying with what Tarantino
(2008) pointed out. Tarantino (2008) suggested that having a six Sigma program in place could
help the organization in many ways. One of them is by reducing variation which is what the
compliance program aims to produce consistently. Finally, adapting a Six Sigma program helps
many pharmaceutical companies to eliminate non-added values and waste and allows production
operations to change effectively. Instead of depending on the final quality control and testing,
Six Sigma allows organizations to detect and expect problems and errors and therefore enhance
the process efficacy which ultimately enhance both quality and compliance. (,2013).
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2.3

Chapter Summary

This chapter section has demonstrated the significant challenges of conducting effective
CAPA program, as well as, the critical success and failure factors. It has provided a historical
overview of CAPA process. Additionally, it has created the legal case for this study research
question as implied from the prior published works. Finally, it has created the support for the
methodology and approach for conducting this research.

21

FRAMEWORK AND METHODOLOGY

The key to improve any process is to understand it well. Understanding the corrective and
preventive action (CAPA) process is the key for enhancing and improving it. Reaching the right
root cause of any quality problem is just the trigger of the CAPA trip. Next, companies need to
design, develop and implement the appropriate and effective actions, either corrective and/or
preventive.
For these implemented actions, it is important to develop and establish a proper process
to measure the effectiveness of these actions in preventing the recurrence of those causes. The
core point is to pay adequate attention to both critical success and failure factors of each phase of
CAPA process.

3.1

Framework

This study defines the Food and Drug Administration (FDA) critical requirements for the
CAPA system that help the pharmaceutical and medical devices companies to evaluate their
current CAPA system performance. Additionally, it defines the criteria that FDA inspector looks
for during CAPA investigations. This will provide the pharmaceutical and medical device
companies with an organized approach to improve the CAPA process using Six Sigma DAMAIC
principle (Define, Measure, Analyze, Improve, and Control). Finally, helping companies to
develop a robust and effective CAPA system for better compliance with FDA regulation, better
customer satisfaction, and good business practices. In this study, all warning letter issued to both
pharmaceutical and medical device companies by the FDA during the last five years will be
evaluated and analyzed and then Six Sigma DMAIC principles will be used to improve the
CAPA system of a medical device company, selected as a case study.
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3.2

Research setting

This section will describe the FDA database and the case study company involved for a
clearer understand of the research.
3.2.1

FDA database

FDA warning letter is the form used by FDA to inform the company with any significant
violation with its regulation. This letter provides detailed description of the found violation. For
examples, poor quality system or violation with manufacturing regulation. In turn, the company
should response to this letter within a specific timeframe. This response should include but not
limited to the action plan(s) that will be used by the company to correct the violation(s) and the
directions with timeframe for the proposed action plan(s). finally, FDA check the adequacy of the
implemented action(s) before taking final decision regarding the company’s compliance status.
All FDA warning letters are available through the FDA website and anyone can access them
through the FDA database (FDA website).
3.2.2

Environment and company

The case study is based on a medical device company regulated by the FDA. This
company wants to improve their CAPA process to achieve the required compliance with the
FDA regulation.
The company originally started as a University-industry partnership with a primary focus
on developing medical devices products. This primary focus rapidly expanded to include other
supportive service areas of pre-clinical, clinical and non-clinical research, medical and scientific
writing, as well as regulatory policies and approaches.
Within this medical device company, this research was conducted on their CAPA process
under their quality assurance department.
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3.3

Methodology

This study uses a variation of methods to answer the previously mentioned research
questions. Due to the nature of this research, the investigation will be based on qualitative
approach. The interest is based on defining the norms and criteria for good CAPA Practice from
the FDA warning letters and define a tool that will help in improving the CAPA process. Two
phases will involve into this study. The first phase will answer the first research question by
defining the criteria for effective CAPA system from the FDA Warning letter. In the second
phase, Six Sigma DMAIC principles will be used to improve the CAPA compliance.
3.3.1

Phase one: Analysis of FDA warning letters

This phase involves the analysis of FDA warning letters from year 2012 to year 2017
using FDA database. The interval between January 2012 till September 2017 is looked at and all
warning letters issued for drug and medical devices that contain CAPA issues are identified via a
manual screening process using the general FDA warning letter database. Moreover, the count of
all warning letters issued to both drug and medical device related companies are derived as well
as the count of warning letters issued for drug and medical devices citing CAPA related issues.
Additionally, companies’ responses to these warning letters are also reviewed to evaluate the
adequacy of their responses.
The output from this phase will be used in the next phase, using Six Sigma DMAIC
principles to improve and enhance the CAPA process within the selected case study company to
bring the best compliance for the company’s CAPA system with the FDA regulation, customer
satisfaction, and good business practices. This output defines the voice of the customer (VOC)
that will serve as the input to the Six Sigma implementation phase.
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3.3.2

Phase two: Six Sigma deployment

Six Sigma is an organized tactical approach aimed to enhance process operation and
other business performance by defining and reducing families of variations which in turn
positively impact all levels of business and quality performance within companies (Rona et al.
2009). In this study, Six Sigma process improvement tool, DMAIC was used to improve the
CAPA process within a medical device company selected as a case study. Five stages represent
the process improvement DMAIC. Stage one is define opportunities, stage two is measure the
current process performance, stage three is analyze opportunity, stage four is to improve
performance, and stage five is to control performance.
3.3.2.1 Stage one: Define opportunity
This stage aimed to define the CAPA process within the case study company by defining
critical customer (FDA) requirements, mapping the process flow, identify and/or validate the
improvement opportunity, develop the business processes.
In this stage, the output results from phase one, analysis of FDA CAPA related warning
letters are defined as the voice of the customer (VOC) which are translated into critical customer
requirements (CCRs). This CCRs are used to identify the critical to quality (CTQ’s) attributes.
which is the output from phase one.
3.3.2.2 Stage two: Measure performance
This second stage of DAMIC was intended to measure the current performance of the
CAPA process within the case study company in order to establish the process base line and
measure the gap between the current performance and the required performance defined
previously from the VOC in the define stage.
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To measure the current performance of the CAPA process within the case study
company, CAPA data are collected for the last 5 years using the case study company CAPA
software. The total number per years, the number of CAPA closed in time, the number of CAPA
extended, and number of preventive/corrective actions validated and checked for effectiveness,
and other performance indicator that help in the determination of process capability are counted.
Additionally, some statistical tools, as histogram, Pareto chart, and run chart are used to show the
current performance of the process.
3.3.2.3 Stage three: Analyze opportunity
The third stage of the DAMIC is the analyze stage. This stage aims to identify and
validate the real root causes of the pre-defined gaps and drawbacks.
Generally, in this phase information and data from the define and measure phase are
collected and analyzed to reach out the real root cause/s for the nonconforming compliance
performance with what the FDA proposed for CAPA system. These is done using five whys
technique.
3.3.2.4 Stage four: Improve performance
The main objectives of the fourth stage are identification, evaluation, and selection of the
right improvement solutions and development of change in management approach to assist the
company in adapting to the changes introduced through solution implementation. These can be
accomplished through generate solution ideas, determine solution impacts, evaluate and select
solutions, and finally, communicate solutions all over the company.
Within the case study company, in the improve stage, both the preferred solutions that
address the root cause of the predetermined drawbacks and the criteria that will be used to
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evaluate these potential solutions are defined and implemented to improve the CAPA process
compliance with the FDA regulation.
3.3.2.5 Stage five: Control performance
This stage aims to determine the approach to be taken to assure achievement of the
targeted results as well as understand how to disseminate lessons learned, standardization
opportunities.
In the control phase, a control plan and transition plan are developed and recommended
to document how the company would maintain their improvements. Additionally, define the
control actions that need to be in place to maintain the improved performance and assure that the
problem does not re-occur as well as assign the responsibility for continued review and the
frequent of the reviews.

3.4

Data collection

This section of chapter three will provide the basic overview of the collection tools that are
used for this particular research project.
3.4.1 FDA warning letters
Warning letter data are collected by accessing The FDA warning letters database through
the Main FDA FOI Warning Letters page. and all warning letter are looked up. The warning
letter that cited CAPA violations through January 2012 to September 2017 are counted and data
related to CAPA violations are collected. Later, all these violations are categorized based on the
information found in the warning letters. In the warning letters the FDA provide and explain to
the company what is wrong with the company’s CAPA system, why the company get this
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warning letter, and whether the response submitted by the company to the FDA accepted or not
and why.
3.4.2

Case study company

The case study company CAPA related data are collected using their software. The
company CAPA procedure is looked up and both the quality manager as well as CAPA
administrator were interviewed – Institutional Review board (IRB) review not need (see
appendix A) - to collect data and gain an insight overview on the current performance of their
CAPA process.

3.5

Chapter Summary

This chapter has described the framework and methodology used in this study. It provided
a detailed description of data collection, how they are obtained, and how they are analyzed.
Throughout that chapter, the actual descriptions of the research setting, and data collection will
be used to report the finding. In addition to research environment description and the methods
used, the next Chapter provides the resulting textural and structural descriptions that are verified
through the focus groups.
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RESULTS AND DISSCUSION

Phase one of this research aimed to conduct an evaluation and assessment to the FDA warning
letters that cited CAPA violation to define the criteria and norms for Good CAPA Practice. On the
other hand, phase two clearly indicates that using Six Sigma DMAIC principle brings best
regulatory compliance to drug and medical devices-based industries, considering the FDA the
customer, and the CAPA process as the FDA required deliverables. First, the results and
discussions focus on the clear identification of the critical customer (FDA) requirements for an
effective CAPA system. Followed by, Discussion of the outcomes of each stage of the five stages
of Six Sigma (DMAIC) implementation to improve the CAPA system within the Case study
medical device company per the FDA critical requirements. Finally, additional benefits of
improved the regulatory process and reduced the cost of non-compliance are discussed as a result
of applying Six Sigma to pharmaceutical and medical devices quality systems.

4.1

Result for phase I: define the norms of Good CAPA practice

The online FDA Warning Letter issued to pharmaceutical companies that cited CAPA
violations are evaluated for the period January 2012 through September 2017. During this 5 years
period, 473 FDA warning letters are issued to pharmaceutical companies, both medical devices
and drugs manufacturers. 266 addressed CAPA violations. 34 out of 266 are not related to the
companies CAPA system itself. Therefore, the total CAPA violations through this time period are
232 (53%). These letters addressed violations with 21 CFR 820.100(a). Medical device and drug
manufacturers face a lot of challenges in maintaining an effective CAPA system per the FDA
requirements. Figure 4.1 shows the finding categories from evaluation and categorizations of the
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FDA warning letters that cited CAPA violation. Basically, five outcomes are the results of this
phase:
1- CAPA system requirements
2- CAPA procedure requirements
3- CAPA reports/ records requirements
4- Why companies get warning letter
5- Point to consider in response to FDA warning letters

Major finding categories from FDA warning letters
that cited CAPA violation

CAPA
CAPA
reports/
CAPA system
procedure
records
requirements requirements
requirements

Why
companies
get warning
letter

Point to
consider in
response to
FDA warning
letters

Figure 4.1 Major categories for CAPA violation in FDA warning letters

Each outcome will be discussed in order to define the norms and criteria for good CAPA
Practice. These norms will help in design and conduct an effective CAPA program easy to
implement and manage. Usually organization start paying attention to their CAPA system
performance when problems arise. effective CAPA program needs to be proactive so that problems
may be fixed at all organizational levels before they occur. Easy implemented program allows the
tracking of both performance and progress with clear and concise results.
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4.1.1 CAPA system requirements
Conducting an effective CAPA system the right way requires clear and concise implementation
and tools. Although it appears simple, achieving a robust system seems to be quite a challenge.
Design and implementing an effective CAPA program requires organizations to adhere to some
major principles. Warning letters addressed nine essential requirements which found to be the
fundamental principle for an effective and robust CAPA system.
1- Adequately documented CAPA activities and/or results.
2- Define and analyze all possible quality data to identify existing and potential causes of
nonconforming or other quality problems, using appropriate statistical methodology.
3- Investigating the cause of nonconformities relating to product, processes, and the quality
system.
4- Identifying the actions needed to correct and prevent recurrence of quality problems.
5- Establish criteria to determine whether corrective action is necessary & establish criteria
for determining whether such corrective action is effective for its CAPAs
6- Define requirements to verify and/or validate actions prior to implementation to ensure
such action is effective; (verification of the effectiveness of corrective actions, or
verification that the corrective action did not adversely affect the finished product)
7- Requirements for Implementing and recording changes necessary to correct and prevent
identified quality problems.
8- Ensuring information related to quality problems or nonconforming product is
disseminated to those directly responsible for assuring the quality of such product or the
prevention of such problems;
9- Submitting relevant information on identified quality problems and CAPA actions for
management review.
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It is important that all levels of the organization’s employees fully understand and be aware
with these ten basic principles and requirements for any CAPA program in order for the system to
be effective and robust. While the whole image from beginning to end might not be seen by each
individual personnel, it is significant that everyone understands each requirement as a part of the
complete system that combines and works together to detect and resolve unpredicted issues.
4.1.2

CAPA procedure requirements

A well written standard operating procedure (SOP) that instructs how to plan, document, and
implement CAPAs is the key point. The way CAPA procedure is written indicate how the
organization deals with their quality and nonconformance events and can be tremendously
revealing the quality and regulatory compliance mindset predominant over the organization.
Figure 4.2 illustrates the critical requirements for CAPA system documentation. Per the FDA for
an effective and robust CAPA system it is important to:
1- Document all corrective and preventive action (CAPA) activities; document the details of
the corrective and preventive actions taken the date of CAPA closure or adequately
describe the results of the investigation, the corrective action effectiveness activities, or the
date of CAPA closure
2- Document effectiveness checks to ensure the action had eliminated the root cause and
would prevent the nonconformance from reoccurring.
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Figure 4.2 CAPA system documentation requirements

4.1.3

CAPA reports/records requirements

Many FDA warning letters that cited CAPA violation addressed violation with either CAPA
records or final reports. This happen when there is major deficiency and weakness in recording the
required essential data and information. Evaluation of these letter revealed that the following
should be included into CAPA records/reports.
1- Investigation results, verification or validation of the corrective and preventive actions
taken to ensure that the actions are effective, and implementation dates of the actions taken
2- Investigating the cause of all nonconformities relating to product, processes and the quality
system, and identifying action(s) needed to correct and prevent recurrence of
nonconforming product and other quality problems.
3- The actions taken to address the nonconformance
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4- A procedure was created or changed to include this corrective action or how/if the
correction action was implemented.
5- Sufficient information to ensure corrective actions are completed and verified as effective
6- The report for CAPA should be fully reviewed and approved and submitted to Executive
Management at the Quality System Management Review meeting for final approval.
Like the final touch of an artist, the records and final report outline the excellent performance,
execution, and compliance of the CAPA activity. The final outcomes of CAPA activity will be a
direct reflection of three essential elements, great mentor, great tools and a solid technique. Having
well designed and well established CAPA processes lead the organization a step further towards
the fundamental goal of total quality and maximum compliance.
4.1.4

Why companies get warning letter

Overall, reviewing the warning letters cited CAPA violations over a 5-year period provide
some insight into how the FDA monitors and addresses CAPA violations. Reviewing these
warning letter however, provides information about why and when pharmaceutical and medical
devices companies get warning letter. Figure 4.3 highlights the major reasons that lead companies
to get a warning letters and a note of violations from the FDA. These major violations that cause
a company to end up with a warning letters are:
1- Failure to establish and maintain procedures for implementing corrective and preventive
action, as required by 21 CFR 820.100(a)
2- Closed CAPA without verifying that all corrective actions are completed.
3- Uncompleted implementation of its corrective actions and CAPA effectiveness
verifications for any observation.
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4- Failed to identify the actions needed to correct and prevent recurrence of nonconforming
product and other quality problems.

Figure 4.3 CAPA violations that lead the FDA to issue a warning letter

Basically, FDA issues warning letters when the organization is found to be non-compliance
with FDA regulations. The warning letter indicates that the organization or firm is in gross noncompliance and violation. Once the Warning letter is issued, it results in very aggressive penalties
that any organization or firm would want to avoid at all costs levels. Therefore, pharmaceutical
and medical device company should have an effective and robust CAPA system in place to ensure
their compliance and avoid facing the cost of non-compliance.
4.1.5

Points to consider in response to FDA warning letters

organization must respond to the Warning Letter promptly with written action plan to
correct the detected violations within the FDA's specified timeframe. A detailed response to each
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observation or violation noted is also required. The quality and promptness of the response to this
letter are extremely important. Companies should respond to the FDA in writing with their
corrective action plan and implement schedule. Generally, FDA gives companies an opportunity
to take professional and rapid corrective action before the agency initiates an enforcement action
(Ayd ,2017).
Evaluation of the FDA warning letter that cited CAPA violation indicate that in response to
any CAPA violation, companies need to provide documentation or evidence of implementing such
corrective actions. Documentation should include but not limited to the following:
1- A copy of the updated CAPA procedure & provide a timeframe for completion of employee
training for the new procedure. The new work instructions and/or revised CAPA procedure
should specify how recurring quality problems will be detected and how risk levels will be
determined.
2- documentation of implementation of the proposed corrective actions, such as training
records and documentation
3- Evidence of using valid statistical methodology for the analysis of quality data, or that a
systemic corrective action was considered to include a retrospective review will include all
sources of quality data.
4- Evidence of the implementation of corrective actions to include a retrospective review of
all CAPAs to verify or validate that the CAPA was effective for previously closed CAPA’s,
to ensure CAPA information was disseminated to those directly responsible for assuring
prevention of such problems, and to ensure that all CAPAs are completed as required.

36
5- Description of the actions taking to prevent the recurrence of similar violations, including
any modifications to the quality review activities to ensure all acceptance activities have
been conducted properly.
Eventually, the results from these five outcomes are the key for reaching out the norms and
criteria for Good CAPA practice which define in the second phase of this research as the voice of
the customer (VOC). To ensure Good CAPA practices, companies need to have:
1- Full detailed procedure for CAPA activities that clearly define all source of quality data
within the company
2- Statistical techniques and tools to analyzing quality data into meaningful performance
that helps identify existing and potential non-compliance issues.
3- Tools and techniques to investigate the potential roots causes.
4- Well established criteria to determine the need for corrective/preventive action
5- To Verify and/or validate actions prior to implementation.
6- To define and implement appropriate corrective/preventive action
7- To implement and record changes necessary to correct/prevent the issue
8- Well establish criteria for effectiveness check of the implemented corrective/preventive
action
9- To ensure dissemination of information related to any non-compliance issue to those
directly responsible for assuring quality.
10- To submit relevant information on identified non-compliance issue and CAPA activities
for management review.
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4.2

Phase II: Six Sigma deployment

First phase results reveal the decisive challenge that companies face in responding to the
complex CAPA regulatory requirements. Ultimately, there is no single model where companies
can just improve all their CAPA system parameters and be confident about their performance to
run their business in the best possible compliance practice.
This section demonstrates the results of using Six Sigma (DMAIC) principles within the
quality system of the case study medical devices company to bring the best compliance
performance within their CAPA system. Using Six Sigma DMAIC principles allows for
developing a universal model that ensure the effective implementation of all CAPA aspects
according to the FAD requirements.
4.2.1 Result for Define stage
The first stage of the DMAIC approach is the define stage. The outputs of this stage are
to set the objectives, clearly identify the problem and develop the problem statement, select the
project team, and finally establish a plan for the next activities. Project charter and the critical
customer (FDA) requirements, from the results of the first phase of this thesis, are developed as
the outcomes of this stages.
The project charter in figure 4.4 outlines exactly what the project will achieve as well as
the identifies the main stakeholders. Moreover, project charter creates a roadmap for the team
members to see the business value of the project and understand how well the project is aligned
with the organizational policy.
On the other hand, critical customer requirements (table 4.1) are identified from the
norms and criteria for good CAPA practices, voice of the customer (VOC) result of the first
phase of this research. For highly regulated industries as medical devices and pharmaceutical
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companies, the customer (FDA) is the final authority that determine the final value of any
regulatory process. FDA decision to approve company’s compliance status is based on complex
system of critical FDA regulation and requirements.

Figure 4.4 Project Charter
Table 4.1 Critical customer requirements
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4.2.2

Result for the Measure stage

In this stage, data are collected and all the personnel within the company who involved in
the CAPA process are interviewed to gain an overview about how the process is currently
performed and determine the magnitude of the non-compliance, in other word how far the current
process performance comply with what defined as the CCRs. Knowing the overall performance of
the current CAPA process is the major important outcomes of this stage.
The SIPOC (Supplier, Input, Process, Output, Customer) tool is used to define who is the customer
for the CAPA process, define all main process inputs and outputs, define the process parameters
and provide a high-level process map to form a baseline for the project. Table 4.2 gives a highlevel understanding of the CAPA process. It describes how the process uses all the relevant inputs,
provided by the CAPA process suppliers, to bring the deliverable output to the CAPA process
customers.
Table 4.2 Process SIPOC
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Another output from the measure phase is the current CAPA process performance.
Therefore, the CAPA system for the case studied company was studied, their software was
accessed, and data are collected in order to gain an insight about their current process performance.
Moreover, from the process map, the gaps and the bottlenecks are identified so these areas can be
targeted. Table 4.1 shows the current process performance. Data collected from the system and
interviewing with both QA manager and CAPA process administrator revealed that there are many
drawbacks within their CAPA system. Moreover, the current CAPA system not include important
sources for quality data like vendor system, customer complains/feedback system, equipment
monitors and calibration system, and even clinical study data are not included until one conformed
as non-conformities. Table 4.3 summarizes the Current CAPA system performance within the case
study company and the gaps within their system.
Table 4.3 Current performance/ GAP within the system
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4.2.3

Result for the Analyze stage

After defining, in the measure stage the gaps that are preventing the company’s CAPA
system from achieving the best compliance performance, the analyze stage is started to answer the
question what causing the problem, in another word, what are the potential causes for these gaps?
In this CAPA system improvement project, the analysis phase is concerned with analysis of the
ways the work is performed in order to identify the reasons why these gaps exist. Figure 4.5
illustrate the 5 whys tool which used to reach out the real root cause. The deliverable root cause,
which is the major output from the analyze stage, is found as no single guideline or CAPA program
approach that guide the company to fulfill all the FDA regulatory requirements or bring the best
practice to the company’s CAPA system.

Figure 4.5 The 5 Whys - Root cause analysis tool
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4.2.4

Result for the improve stage

Now, after reaching out the real root cause of the problem, here comes the turn for the
improve stage to start. The improve stage mainly involves developing of feasible solutions
followed by implementation of these solutions to solve the issue and close the gaps in order to
achieve a near perfection CAPA system compliance. After careful evaluation and analysis, it was
revealed that the system need to redesign to include all the norms and criteria for good CAPA
practice. Figure 4.6 illustrates CAPA process turtle which includes all the aspects of the CAPA
process that based upon Six Sigma DMAIC principles to include process input, required
competence and skills, other support process, outputs, and performance indicators to measures
process performance. Using CAPA process turtle revels the needs to Design a new model able to
cover all the required criteria. This proposed model is a stepwise approach as each step acts as an
input to the next step. It consists of 11 steps that cover all the CAPA system regulatory
requirements and ensure the best CAPA practices.
1. Problem Identification
2. Risk assessment and impact assessment
3. Event evaluation and remedial action initiation
4. Corrections
5. Data gathering and analysis
6. Root cause analysis
7. Corrective and preventing action
8. Implementation and follow-up
9. Effectiveness check
10. Monitor for reoccurrence
11. Management oscillation and review
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Figure 4.6 CAPA process turtle

To test the proposed model, One CAPA problem from the company CAPA system was
sampled and the new designed model was applied in order to gain an overview about the
effectiveness of the new model. The new model allows both quantification and qualification
analysis of the issue, additionally, provides a clear understand of the great image of the CAPA
system as a part of the total quality management system for the company, and covers all the
aspects for Good CAPA practices.

4.2.5

Result for the control stage

Here comes the last stage of Six Sigma DAMIC deployment, the control stage. Some control
ideas are recommended and suggested to the case study company in order to maintain this
compliance performance improvement. These ideas include:
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1- Creating a CAPA checklist to ensure that all CAPA regulatory requirements are covered
during CAPA detection and execution.
2- Using tracking and monitor tool to record and monitor all CAPA activities
3- Categorization of the CAPA finding to facilitate tracking process.
4- Develop a metrics to measure CAPA process performance and capability.

4.3

Chapter summary

This chapter presents the results of this research. It describes the five outcomes result from
evaluation of FDA warning letters cited CAPA violation followed by detail description of each
stage of Six Sigma implementation within the case study company. The coming chapter presents
the final conclusion and recommendations for future work.
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CONCLUSION AND RECOMMENDATION

There is no doubt that CAPA is a formalized fundamental process that should permanently
include a corrective action (how to immediately correct the exist nonconformance), an
investigation of the root cause(s), a plan to eliminate the risk of the recurrence of the issue based
on the investigation findings, and effectiveness check to be certain that these will create the desired
compliance performance. Eventually, all organization should have a solid well written SOP in
place to define what initiates a CAPA and what is the procedure to follow.
Currently, there is no specific guideline or model describing how to design and create a
compliance CAPA system. This rational the reason why pharmaceutical and medical device
companies usually struggle with implementing FDA regulations and requirements concerning
CAPA system. While companies usually pay attention to the corrective/preventive actions taken
to correct the non-compliance issue, they missed out how to check and measure both the
effectiveness and the impact of the action taken on the overall company’s quality system, basically,
this is the focus of an FDA inspector during regular FDA inspection. During the FDA inspection,
regarding the company’s CAPA system, the inspector checks how CAPA initiate within the
company, tracing the identified root cause, the effectiveness measure of the action taken, the
impact and risk assessment on all quality aspects, spreading of CAPA related information, how
CAPA escalate to top management, and finally, check the completed CAPA documentation,
procedure, records, and reports.
On the other hand, FDA does not care about any hard work and costs paid by the company to
rebuild and implement a robust CAPA system. Companies need to effectively respond to FDA
warning letter, if not, FDA can escalates using legal channels to enforce these companies to make
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compliance changes. Therefore, this thesis tried to help pharmaceutical and medical device
companies to reach high perfection level of CAPA compliance.
Pharmaceutical/medical devices-based industry need to comply with all FDA regulation to
avoid the cost of non-compliance, conduct better business practice, and improve customer
relationship. This study develops a new CAPA model, the key with this new proposed model is to
understand how to implement this model across all the organizational level. Eventually, company
need to make sure that the all required knowledge and tools are available within the organization
structure to ensure the effective execution of this new proposed CAPA model.

5.1

Conclusion

There is no generalized or standardized procedure for design, implement, and control a
compliance CAPA structure. However, this research provides a universal model along with
tactical way and methodology that will help companies implementing this new model.
FDA warning letters provide a great tool for professionals and researchers to understand
how to build in and implement the FDA regulations and requirements into companies’ quality
system. Additionally, adopting Six Sigma helps improving CAPA system compliance
performance. Moreover, using Six Sigma DMAIC approach helps in defining the bottlenecks as
well as the different sources of variations within CAPA process.
A stepwise-based CAPA model is the best way to ensure the best compliance with FDA
requirements and regulations for effective CAPA structure. Using a well-developed checklist
helps approving that the whole course of CAPA is efficiently accomplished at all Quality and
business levels. This CAPA model significantly helps companies in their continuous improvement
journey to reach out their ultimate goals in all aspects of the business.
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Figure 5.1 CAPA system performance improvement with Six Sigma principle wheels

This thesis advocates for CAPA process changes toward best compliance performance, as
well as recommends new procedures and measures, that can be implemented to control this
compliance performance and reduce the cost of non-compliance in the future. Figure 5.1 Shows
the CAPA process improvement wheel and how the use of Six Sigma DMAIC principle allows
for the developing of a universal CAPA model, implement CAPA aspects, and ultimately,
control and maintain this improved performance. To conclude, this model helps the company to
follow and implement all the required aspect for an effective and robust CAPA system comply
with the FDA regulations.
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5.2

Recommendation for future work

More empirical research is needed to statistically test the significance of the new proposed
model. Additionally, generalizability of this new model should be examined by applying it to
various case studies companies.
Although, the effect of Six Sigma implementation in improving the organizational
compliance performance is especially interesting to research, there is relatively insufficient
scientific research on Six Sigma application recently available regarding pharmaceutical sector
especially in improving compliance performance. Therefore, further research is required to
extend the overall knowledge, understanding, and application of Six Sigma within this huge
industrial sector, which definitely helps to better implement and apply Six Sigma successfully to
this huge and special sector in order to achieve near perfection compliance performance.
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APPENDIX A: IRB REVIEW DETERMINATION LETTER
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